Dosing

PreclinicalSmall molecule

HHIV Prevention Trials Network

Dosing is one of 5 small molecule programs targeting PCSK9 Inhibitor. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PCSK9 InhibitorCompleted

PCSK9 InhibitorPreclinical

Completed

Competition

Competitive Landscape

5 competitors in PCSK9 Inhibitor

#DrugCompanyPhaseTrials

Praluent

Regeneron

Approved

2 2

Enlicitide

Merck & Co.

Phase 3

1 3

PCSK9 Inhibitor

YYun Dai Chen

Phase 3

2 4

Recaticimab

SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 3

1 5

Dosing

HHIV Prevention Trials Network

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pre-Exposure Prophylaxis (PrEP)1 trial

The ADAPT Study: Use of Emtricitabine and Tenofovir Disoproxil Fumarate for Pre-Exposure Prophylaxis (PrEP)

Completed·HHIV Prevention Trials Network·Phase 2·NCT01327651·622 enrolled

PCSK9 Inhibitor1 trial

INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers

Completed·—·N/A·NCT03273972·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Dosing. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dosing compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dosing. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — HIV Prevention Trials Network company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: HHIV Prevention Trials Network

Dosing

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pre-Exposure Prophylaxis (PrEP)1 trial

PCSK9 Inhibitor1 trial

References

Drug Info

Quick Facts

Related News